| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
1 Neonatal Intensive Care Unit, King's College Hospital, Denmark Hill, London SE5 9RS, UK
2 Department of Clinical Neurophysiology, King's College Hospital
Correspondence to:
Correspondence to:
G B Boylan, NICU, 4th Floor, Ruskin Wing, King's College Hospital, Denmark Hill, London SE5 9RS, UK;
geraldine.boylan{at}kcl.ac.uk
Aims: To evaluate the effectiveness of phenobarbitone as an anticonvulsant in neonates.
Methods: An observational study using video-EEG telemetry. Video-EEG was obtained before treatment was started, for an hour after treatment was given, two hours after treatment was given, and again between 12 and 24 hours after treatment was given. Patients were recruited from all babies who required phenobarbitone (20–40 mg/kg intravenously over 20 minutes) for suspected clinical seizures and had EEG monitoring one hour before and up to 24 hours after the initial dose. An EEG seizure discharge was defined as a sudden repetitive stereotyped discharge lasting for at least 10 seconds. Neonatal status epilepticus was defined as continuous seizure activity for at least 30 minutes. Seizures were categorised as EEG seizure discharges only (electrographic), or as EEG seizure discharges with accompanying clinical manifestations (electroclinical). Surviving babies were assessed at one year using the Griffiths neurodevelopmental score.
Results: Fourteen babies were studied. Four responded to phenobarbitone; these had normal or moderately abnormal EEG background abnormalities and outcome was good. In the other 10 babies electrographic seizures increased after treatment, whereas electroclinical seizures reduced. Three babies were treated with second line anticonvulsants, of whom two responded. One of these had a normal neurodevelopmental score at one year, but the outcome for the remainder of the whole group was poor.
Conclusion: Phenobarbitone is often ineffective as a first line anticonvulsant in neonates with seizures in whom the background EEG is significantly abnormal.
Keywords: phenobarbitone; anticonvulsant; seizure; EEG; video-EEG
Related Article
Arch. Dis. Child. Fetal Neonatal Ed. 2002 86: F142.
This article has been cited by other articles:
|
|
 |
|
  D. Sirsi, S. Nangia, J. LaMothe, B. E. Kosofsky, and G. E. Solomon Successful Management of Refractory Neonatal Seizures With Midazolam J Child Neurol, June 1, 2008; 23(6): 706 - 709. [Abstract] [PDF]
|
|
|
|
 |
|
 D M Murray, G B Boylan, I Ali, C A Ryan, B P Murphy, and S Connolly Defining the gap between electrographic seizure burden, clinical expression and staff recognition of neonatal seizures Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2008; 93(3): F187 - F191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Clancy Summary proceedings from the neurology group on neonatal seizures. Pediatrics, March 1, 2006; 117(3 Pt 2): S23 - S27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L S de Vries and L Hellstrom-Westas Role of cerebral function monitoring in the newborn Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2005; 90(3): F201 - f207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Castro Conde, A. A. Hernandez Borges, E. D. Martinez, C. G. Campo, and R. P. Soler Midazolam in neonatal seizures with no response to phenobarbital Neurology, March 8, 2005; 64(5): 876 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M Rennie, G Chorley, G B Boylan, R Pressler, Y Nguyen, and R Hooper Non-expert use of the cerebral function monitor for neonatal seizure detection Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2004; 89(1): F37 - F40. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| ARCH DIS CHILD | FETAL NEONATAL ED | ED PRACTICE |
